Tonix Pharmaceuticals Holding Corp (TNXP)

[Ruben3009]

Tonix Pharmaceuticals is working on many products, nothing has hit the pipeline yet.
See below: these products are years away.


TNX-102 SL Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling
Mid-Phase III

TNX-102 SL Posttraumatic Stress Disorder (PTSD)
Phase II start — targeting 2Q 2022
Phase II

TNX-102 SL Long COVID
Phase II start — targeting 2Q 2022
Phase II

TNX-601 CR Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids*
Phase II start — targeting 1Q 2023
Phase I

TNX-1300 Cocaine Intoxication / Overdose
Phase II start — targeting 2Q 2022
Phase II

TNX-1900 Chronic Migraine
Phase II start — targeting 2H 2022
Phase II
* Pending IND Clearance


Immunology Portfolio

TNX-1500 Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 2H 2022
Preclinical

TNX-1700 Gastric and Colorectal Cancers
Preclinical


Infectious Disease Portfolio

TNX-102 SL Long COVID
Phase II start — targeting 2Q 2022
Phase II

TNX-1840/TNX-1850 COVID-19 Vaccine
Preclinical

TNX-3500 COVID-19 Small Molecule Antiviral
Preclinical

TNX-801 Smallpox and Monkeypox Preventing Vaccine
Preclinical


Rare Disease Portfolio

TNX-2900 Prader-Willi Syndrome
FDA Orphan Drug Designation
Preclinical